Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 2 patents
15 readers on Mendeley
  • Article usage
  • Citations to this article (63)

Advertisement

Research Article Free access | 10.1172/JCI115769

High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia.

W Digel, F Porzsolt, M Schmid, F Herrmann, W Lesslauer, and M Brockhaus

Department of Internal Medicine III, University of Ulm, Federal Republic of Germany.

Find articles by Digel, W. in: PubMed | Google Scholar

Department of Internal Medicine III, University of Ulm, Federal Republic of Germany.

Find articles by Porzsolt, F. in: PubMed | Google Scholar

Department of Internal Medicine III, University of Ulm, Federal Republic of Germany.

Find articles by Schmid, M. in: PubMed | Google Scholar

Department of Internal Medicine III, University of Ulm, Federal Republic of Germany.

Find articles by Herrmann, F. in: PubMed | Google Scholar

Department of Internal Medicine III, University of Ulm, Federal Republic of Germany.

Find articles by Lesslauer, W. in: PubMed | Google Scholar

Department of Internal Medicine III, University of Ulm, Federal Republic of Germany.

Find articles by Brockhaus, M. in: PubMed | Google Scholar

Published May 1, 1992 - More info

Published in Volume 89, Issue 5 on May 1, 1992
J Clin Invest. 1992;89(5):1690–1693. https://doi.org/10.1172/JCI115769.
© 1992 The American Society for Clinical Investigation
Published May 1, 1992 - Version history
View PDF
Abstract

The presence of soluble tumor necrosis factor (TNF) binding proteins (BP) was investigated in the sera of healthy volunteer blood donors and cancer patients. Two distinct types of TNFBP, types A and B, which are immunologically related to the cellular 75-kD TNF receptor (TNFR) and the cellular 55-kD TNFR, respectively, were assessed by immunoassays using nonblocking anti-receptor antibodies and 125I-recombinant human TNF alpha. As compared to the titers observed in 25 healthy controls, TNFBP types A and B titers were found to be elevated in almost all sera obtained from patients with underlying malignant disease. The highest amounts of TNFBP were seen in the sera of patients with B cell malignancies including hairy cell leukemia (HCL) and type B chronic lymphocytic leukemia. Treatment of HCL patients with recombinant human interferon-alpha was associated with decrease of circulating TNFBP.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1690
page 1690
icon of scanned page 1691
page 1691
icon of scanned page 1692
page 1692
icon of scanned page 1693
page 1693
Version history
  • Version 1 (May 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (63)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
15 readers on Mendeley
See more details